Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK (J S de Bono FRCP); Tulane University, New Orleans, LA, USA (A O Sartor MD); Hôpital Européen Georges Pompidou, Paris, France (S Oudard MD); Istanbul University, Istanbul, Turkey (M Ozguroglu MD); Odense University Hospital, Odense, Denmark (S Hansen MD); Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium (J-P Machiels MD); Masarykuv Onkologicky Ustav, Brno, Czech Republic (I Kocak MD); Institut Paoli Calmette Hôpital de Jour, Marseille, France (G Gravis MD); Orszagos Onkologiai Intezet, Kemoterapia C, Budapest, Hungary (I Bodrogi MD); London Health Sciences Centre, London, ON, Canada (M J Mackenzie MD); and Sanofi -Aventis, Malvern, PA, USA (L Shen PhD, S Gupta MD, M Roessner MS)